← Eichor
Study identifier: NCT06965764 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Contrast - Induced Nephropathy After Intravenous Contrast Procedures at Sohag University Hospitals

Condition: Contract Induced Nephropathy  ·  Sponsor: Sohag University

PhaseN/A
Planned participants200
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Contrast-induced nephropathy (CIN) is a serious complication of angiographic procedures and results from administration of iodinated contrast media (CM). CIN is the third most common cause of hospital acquired acute renal injury representing about 12% of the cases. The reported incidence of CIN varies widely across the literature, depending on the patient population studied and the baseline risk factors . An overall incidence of CIN following intraarterial contrast injection in the general population was reported to be 0.6-2.3%. Although the incidence of CIN is low in patients with normal renal function, its prevalence can be much higher in several patient subsets e.g. diabetics, patients with existing renal insufficiency. Contrast-induced nephropathy is defined as a rise in serum creatinine of at least 0.5 mg/dL or a 25% increase from baseline within 48 to 72 hours after contrast exposure. The Kidney Disease Improving Global Outcome (KDIGO) definition is different, with stage 1 being a rapid rise of creatinine to greater than 0.3 mg/dL within 48 hours or the relative rise of 50% or more from baseline in 7 days or less or a reduction in urine output to less than 0.5 ml/kg/hr for 6 to 12 hours. This severity is further staged based on creatinine levels, urine output, or the need for renal replacement therapy. In most cases of CIN there is an asymptomatic, non-oliguric rise of serum creatinine within 24hours; however, in more severe cases, the creatinine concentration may n…

This description comes directly from the study's public registry record.

Talk to the study team

Esraa R Youssef, Resident  ·  +201121932876  ·  esraa_ragab_post@med.sohag.edu.eg

Usama A Arafa, professor  ·  +201063064007

Always discuss trial participation with your own doctor first.

Locations (2)

Sohag university hospitalsSohag, EgyptRecruiting
Sohag university hospitalsSohag, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06965764